Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.68 |
| ▸ | JAK1 | P23458 | 7/20 | 0.67 |
| ▸ | JAK3 | P52333 | 4/20 | 0.67 |
| ▸ | TYK2 | P29597 | 3/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.67 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.67 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.67 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.67 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | CIT | O14578 | 1/20 | 0.48 |
| ▸ | GAK | O14976 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | ULK1 | O75385 | 1/20 | 0.48 |
| ▸ | PRKCB | P05771 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13695723 | 0.93 | JAK2 (0.65) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL13774665 | 0.87 | JAK2 (0.61) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL13695626 | 0.85 | JAK2 (0.66) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL13695724 | 0.84 | JAK2 (0.62) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL101195 | 0.82 | JAK2 (0.62) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL28340692 | 0.82 | JAK2 (0.61) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL101593 | 0.82 | JAK2 (0.62) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL27741963 | 0.82 | JAK2 (0.65) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL17748809 | 0.81 | JAK2 (0.66) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL30589328 | 0.80 | AURKA (0.62) | JAK2HDAC6HDAC1JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027606-A1 | BIOMARKERS FOR GRAFT-VERSUS-HOST DISEASE | INCYTE CORPORATION | 2023-01-26 | — | — | US | disclosed |
| US-11406640-B2 | JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction | INCYTE CORPORATION (US) | 2022-08-09 | — | — | US | disclosed |
| US-20200281931-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CHRONIC LUNG ALLOGRAFT DYSFUNCTION | INCYTE CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-20190111058-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190111058-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | JAK1, JAK2, JAK3 | JAK2 2/4885HDAC6 1978/4885HDAC1 2228/4885 |
| US-20200281931-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CHRONIC LUNG ALLOGRAFT DYSFUNCTION | JAK1, JAK3, STAT1 | JAK2 4/4885HDAC6 1201/4885HDAC1 2392/4885 |
| US-11406640-B2 | JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction | JAK1, JAK3, STAT1 | JAK2 4/4885HDAC6 1201/4885HDAC1 2392/4885 |
| US-20230027606-A1 | BIOMARKERS FOR GRAFT-VERSUS-HOST DISEASE | CD74, HLA-DRB1, TSG101 | JAK2 26/4885HDAC6 2261/4885HDAC1 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.